Floatz logo

Ciltacabtagene Autoleucel

Plasma Cell Leukemia

St. Olavs HospitalCell therapyActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
73/ 100

Competitive context

40 Active assets in the Plasma Cell Leukemia cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Institute of Hematology & Blood Diseases Hospital, China
Phase 2BB
Fludarabine
Masonic Cancer Center, University of Minnesota
Phase 2BB
cc-5013
National Cancer Institute (NCI)
Phase 3B
DEXAMETHASONE
National Cancer Institute (NCI)
Phase 3B
Evomela
National Cancer Institute (NCI)
Phase 2B

View all 50 →

Same molecule, other indications

Ciltacabtagene Autoleucel is also rated in:

smoldering plasma cell myelomaDormant
CCC
Indicative ·
53 / 100
View asset →
plasma cell myelomaDormant
CCC
Indicative ·
50 / 100
View asset →
AL amyloidosisDormant
D
Indicative ·
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →